OPRT:NASDAQOportun Financial Corporation Analysis
Data as of 2026-05-21 - not real-time
$5.41
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Oportun has delivered a sixth straight quarter of GAAP profitability and reinforced its balance sheet, supporting the recent positive earnings guidance. Technical momentum is neutral with the short‑term moving average modestly above the medium‑term average, while the relative strength index hovers around the midpoint, suggesting neither strong buying nor selling pressure. The MACD pattern has turned bearish and volume trends are decreasing, placing the stock near a key support level and below a clear resistance zone. Valuation metrics highlight a stark gap between market price and intrinsic value, with the discounted cash‑flow model indicating substantial upside. However, the stock exhibits a high beta and elevated 30‑day volatility, reflecting heightened market sensitivity and a sizable historical drawdown. Upcoming earnings and the rollout of risk‑based pricing in the second half of the year could act as catalysts for price movement.
Given the blend of solid fundamentals, strong cash generation, and a mission‑driven niche, the long‑term outlook remains favorable despite short‑term technical softness. The absence of a dividend and a capital‑intensive balance sheet temper expectations, but the low price‑to‑book and price‑to‑sales ratios reinforce a value‑oriented investment case. Market sentiment is currently in an “extreme greed” phase, which may provide additional short‑term momentum if earnings meet expectations. Overall, the company appears undervalued with upside potential, though investors should remain mindful of its volatility and sector‑specific credit risks.
Given the blend of solid fundamentals, strong cash generation, and a mission‑driven niche, the long‑term outlook remains favorable despite short‑term technical softness. The absence of a dividend and a capital‑intensive balance sheet temper expectations, but the low price‑to‑book and price‑to‑sales ratios reinforce a value‑oriented investment case. Market sentiment is currently in an “extreme greed” phase, which may provide additional short‑term momentum if earnings meet expectations. Overall, the company appears undervalued with upside potential, though investors should remain mindful of its volatility and sector‑specific credit risks.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Technical indicators show bearish MACD and falling volume
- Price is near a defined support level
- Upcoming earnings could confirm momentum direction
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation discount to DCF fair value
- Consistent profitability and strong cash flow generation
- Positive earnings guidance and risk‑based pricing rollout
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Fundamentally undervalued with low price‑to‑book and price‑to‑sales ratios
- Mission‑driven niche in credit services offering stable demand
- Long‑term upside potential reflected in intrinsic value estimates
Key Metrics & Analysis
Financial Health
Revenue Growth1.30%
Profit Margin2.45%
P/E Ratio14.6
ROE4.68%
ROA0.56%
Debt/Equity685.78
P/B Ratio0.6
Op. Cash Flow$416.2M
Industry P/E16.7
Technical Analysis
TrendNeutral
RSI49.0
Support$5.10
Resistance$6.14
MA 20$5.61
MA 50$5.17
MA 200$5.46
MACDBearish
VolumeDecreasing
Fear & Greed Index91.27
Valuation
Fair Value$29.91
Target Price$8.50
Upside/Downside57.12%
GradeUndervalued
TypeValue
Risk Assessment
Beta2.12
Volatility55.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.